secwatch / observer
8-K filed August 10, 2022, 7:59 PM ET ticker NAGE CIK 0001386570
earnings confidence high sentiment negative materiality 0.75

ChromaDex Q2 net sales $16.7M (-5% YoY); CFO Farr terminated, Gerber interim CFO

Niagen Bioscience, Inc.

2022-Q2 EPS reported -$0.21 revenue$33,991,000
item 2.02item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hamed Shahbazi

Director
NAGE · Niagen Bioscience, Inc.
Effective
2022-08-09
Filed
August 10, 2022, 7:59 PM ET
On August 8, 2022, the Board appointed Hamed Shahbazi as a member of the Board effective as of August 9, 2022, to serve until the Company’s 2023 annual meeting of stockholders and until his successor is duly elected and qualified.
Appointed (interim)

Brianna Gerber

SVP, Finance / Interim Chief Financial Officer
NAGE · Niagen Bioscience, Inc.
Effective
2022-08-11
Filed
August 10, 2022, 7:59 PM ET
On August 10, 2022, the Board of Directors of ChromaDex (the “Board”) appointed Brianna Gerber as SVP, Finance / Interim Chief Financial Officer, effective as of August 11, 2022, to replace the vacancy created by Mr. Farr’s termination as disclosed in item (a) above.
Departed

Kevin Farr

Chief Financial Officer
NAGE · Niagen Bioscience, Inc.
Effective
2022-08-12
Successor
Brianna Gerber
Filed
August 10, 2022, 7:59 PM ET
On August 10, 2022, Kevin Farr was terminated without cause as Chief Financial Officer of the Company, and as an officer, employee, and director of the Company and any subsidiaries of the Company in which he serves in any of those capacities, effective as of August 12, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hamed Shahbazi was appointed as Director at Niagen Bioscience, Inc..

Action
appointed
Role
Director
Exact text from the filing
On August 8, 2022, the Board appointed Hamed Shahbazi as a member of the Board effective as of August 9, 2022, to serve until the Company’s 2023 annual meeting of stockholders and until his successor is duly elected and qualified.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brianna Gerber was appointed as SVP, Finance / Interim Chief Financial Officer at Niagen Bioscience, Inc..

Action
appointed
Role
SVP, Finance / Interim Chief Financial Officer
Exact text from the filing
On August 10, 2022, the Board of Directors of ChromaDex (the “Board”) appointed Brianna Gerber as SVP, Finance / Interim Chief Financial Officer, effective as of August 11, 2022, to replace the vacancy created by Mr. Farr’s termination as disclosed in item (a) above.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Farr departed as Chief Financial Officer at Niagen Bioscience, Inc..

Action
terminated without cause
Role
Chief Financial Officer
Exact text from the filing
On August 10, 2022, Kevin Farr was terminated without cause as Chief Financial Officer of the Company, and as an officer, employee, and director of the Company and any subsidiaries of the Company in which he serves in any of those capacities, effective as of August 12, 2022.
View on SEC.gov

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR
accession 0001851734-22-000422
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.